On December 13, the U.S. Securities and Exchange Commission’s (SEC) Division of Corporation Finance staff (the staff) updated its Compliance & Disclosure Interpretations (CD&Is), concerning the use of non-generally accepted...more
As part of their growth strategy, private biotech and pharmaceutical companies often seek to raise capital through initial public offerings (IPOs). In addition to raising capital, an IPO can give a life sciences company a...more
Investors are still feeling the burn from biotech’s flameout. And with rising interest rates and increasingly strict regulatory scrutiny, it’s no wonder they remain wary of being singed by the sector.
Originally published...more
On February 9, the Securities and Exchange Commission (SEC) proposed rule amendments to shorten the standard securities settlement cycle for most broker-dealer transactions to one business day after the trade date (commonly...more
On February 10, the Securities and Exchange Commission (SEC) proposed rule amendments to modernize beneficial ownership reporting under Sections 13(d) and 13(g) of the Exchange Act. Under the current rules, beneficial owners...more
On December 15, the Securities and Exchange Commission (SEC) proposed rule amendments regarding the availability of the Rule 10b5-1(c)(1) affirmative defense to insider trading liability and enhanced disclosure requirements....more
On August 26, the U.S. Securities and Exchange Commission (SEC) adopted amendments expanding the definition of “accredited investor” to allow additional categories of investors to invest in unregistered private offerings. The...more
8/28/2020
/ Accredited Investors ,
Amended Regulation ,
Corporate Issuers ,
Employee Retirement Income Security Act (ERISA) ,
Investment Adviser ,
Investment Advisers Act of 1940 ,
Limited Liability Company (LLC) ,
Private Equity ,
Private Offerings ,
Privately Held Corporations ,
Registration Requirement ,
Regulation D ,
Rule 144A ,
Rural Business Investment Companies (RBICs) ,
Securities Act of 1933 ,
Securities and Exchange Commission (SEC) ,
Venture Capital
On April 16, the Nasdaq Stock Market issued Nasdaq Issuer Alert 2020-2, announcing a proposal for temporary relief for companies listed on the exchange with respect to stock prices and market values that have fallen below...more
On March 31 and April 6, the U.S. Securities and Exchange Commission (SEC) issued Compliance and Disclosure Interpretations (C&DIs) to provide additional clarity regarding the SEC’s COVID-19 Order issued on March 4 and...more
On April 6, Delaware Gov. John Carney issued the Tenth Modification of the Declaration of a State of Emergency for the State of Delaware Due to a Public Health Threat (Emergency Order), arising from the COVID-19 epidemic. ...more
In light of the rapid pace of developments related to the coronavirus disease 2019 (COVID-19) pandemic, Nasdaq has issued a memorandum for Nasdaq-listed companies regarding the pandemic’s impact on the exchange and certain...more
More than ever, life sciences companies are going public to raise capital for future growth. In fact, U.S. equity financing in life sciences skyrocketed to a record $7 billion in 2018—a 69 percent jump over the year...more
2/8/2019
/ Accounting Standards ,
Capital Formation ,
Capital Markets ,
Disclosure Requirements ,
Emerging Growth Companies ,
Initial Public Offering (IPO) ,
Internal Controls ,
Investment Banks ,
Life Sciences ,
Popular ,
Regulatory Standards ,
Reporting Requirements ,
Sarbanes-Oxley ,
Startups ,
Stock Exchange ,
Transparency
The SEC’s rule changes further streamline the pathway for many companies to conduct their initial public offerings and reduce the burdens associated with their subsequent SEC periodic reporting obligations.
On January...more